- Home
- BRVE vs PGEN Comparison
BRVE vs PGEN Comparison
Compare BRVE & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRVE | PGEN |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BRVE | PGEN |
|---|---|---|
| Price | $24.64 | $6.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 321.2K | ★ 6.3M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | N/A | $81.04 |
| P/E Ratio | ★ N/A | $231.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.61 | $2.99 |
| 52 Week High | $32.00 | $7.72 |
Technical Indicators
Market Signals| Indicator | BRVE | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 54.60 |
| Support Level | N/A | $3.96 |
| Resistance Level | $29.68 | $7.32 |
| Average True Range (ATR) | 2.06 | 0.40 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 0.55 | 49.24 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.